Key Developments: Halozyme Therapeutics Inc (HALO.A)

HALO.A on American Stock Exchange

15.78USD
27 Apr 2015
Change (% chg)

-- (--)
Prev Close
$15.78
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,339
52-wk High
$17.25
52-wk Low
$6.98

Search Stocks

Latest Key Developments (Source: Significant Developments)

Halozyme Therapeutics Inc reaffirms FY 2015 revenue outlook
Monday, 2 Mar 2015 04:15pm EST 

Halozyme Therapeutics Inc:Expects FY 2015 net revenues to be in the range of $85 - $95 mln.  Full Article

Halozyme Therapeutics Inc gives FY 2015 revenue guidance below analysts' estimates - Conference Call
Wednesday, 7 Jan 2015 10:00am EST 

Halozyme Therapeutics Inc:Estimates FY 2015 net revenues in the range of $85 million to $95 million.FY 2015 revenue of $98 million - Thomson Reuters I/B/E/S.  Full Article

Halozyme Therapeutics Inc receives FDA approval for additional manufacturing facilities for Hylenex Recombinant
Monday, 20 Oct 2014 08:29am EDT 

Halozyme Therapeutics Inc:That the U.S. Food and Drug Administration (FDA) has approved new contract manufacturing facilities used in the production of Hylenex recombinant (hyaluronidase human injection).The FDA approved use of Cook Pharmica manufacturing facility in Bloomington, Indiana for the production of bulk rHuPH20, active ingredient used in Hylenex, and Patheon facility in Greenville, North Carolina, for production of finished Hylenex product.  Full Article

Halozyme Therapeutics receives orphan drug designation for PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer
Friday, 3 Oct 2014 07:45am EDT 

Halozyme Therapeutics Inc:Announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer.Says the FDA Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.  Full Article

Halozyme Therapeutics Inc consistent 1 trial of hylenex recombinant meets primary endpoint
Monday, 31 Mar 2014 08:00am EDT 

Halozyme Therapeutics Inc:Says primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial.The trial is evaluating Hylenex recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes.With respect to secondary endpoints, the rate of overall hypoglycemic events (serum glucose of 70mg/dL) in the combined treatment groups was reduced by 12 pct (p=.08) compared to the control group.  Full Article

Halozyme Therapeutics Inc announces roche marketing authorization for MabThera SC for patients with common forms of non-Hodgkin Lymphoma In European Union
Friday, 28 Mar 2014 08:00am EDT 

Halozyme Therapeutics Inc:European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.  Full Article

Halozyme Therapeutics Inc announces positive results from phase 1/2 clinical trial in Cellulite With HTI-501
Tuesday, 25 Mar 2014 08:00am EDT 

Halozyme Therapeutics Inc:Top-line data from proof of concept Phase 1/2 clinical trial evaluating the use of HTI-501 in the treatment of cellulite.Primary endpoint of clinical trial was met, showing statistically significant improvement in appearance of cellulite in areas of patients' skin.Treated with HTI-501 as determined by physician assessment 28 days after treatment compared to same skin areas prior to treatment and skin areas treated with vehicle control.In follow up, effect, as assessed by physician assessment, was maintained at three and six months.  Full Article

Halozyme Therapeutics Inc announces closing of public offering of common stock
Monday, 10 Feb 2014 04:15pm EST 

Halozyme Therapeutics Inc:Says the closing of its previously announced public offering of 8,846,153 shares of common stock, including 1,153,846 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $13.00 per share.Says the net proceeds from this offering are expected to be about $107.8 mln.Says J.P. Morgan Securities LLC and Citigroup acted as joint book-running managers for the offering. Piper Jaffray and BMO Capital Markets acted as co-managers for the offering.  Full Article

Halozyme Therapeutics Inc prices public offering of common stock
Tuesday, 4 Feb 2014 08:45pm EST 

Halozyme Therapeutics Inc:Says the pricing of its previously announced underwritten public offering of 7,692,307 shares of its common stock at a public offering price of $13.00 per share.All of the shares in the offering are being sold by Halozyme.Says the offering is expected to close on Feb. 10, 2014 subject to customary closing conditions.Says in addition, Halozyme has granted the underwriters a 30-day option to purchase up to an additional 1,153,846 shares of common stock.Says J.P. Morgan Securities LLC and Citigroup are acting as joint book-running managers for the offering.Says Piper Jaffray & Co. and BMO Capital Markets are acting as co-managers for the offering.Says Halozyme intends to use the net proceeds from this offering to fund research and development of proprietary programs, including the potential acceleration of the PEGPH20 program, and for other general corporate purposes.  Full Article

Halozyme Therapeutics Inc announces public offering of common stock
Monday, 3 Feb 2014 04:01pm EST 

Halozyme Therapeutics Inc:Says it has commenced an underwritten public offering of $100,000,000 of shares of its common stock.Says all of the shares in the offering are to be sold by Halozyme.Says it intends to grant the underwriters a 30-day option to purchase up to $15,000,000 of additional shares.The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.J.P. Morgan Securities LLC and Citigroup are acting as joint book-running managers for the offering.  Full Article

RPT-INTERVIEW-Halozyme CEO sees blockbuster potential in its cancer drug

NEW YORK, Jan 7 - Halozyme Therapeutics Inc believes it has a multibillion-dollar cancer drug on its hands.

Search Stocks